(NP (NP Role/NN) (PP for/IN (NP the/DT Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD)) (PP in/IN (NP (NP viral/JJ promoter/NN switching/VBG) (PP-TMP during/IN (NP (NP initial/JJ stages/NNS) (PP of/IN (NP infection/NN)))))) ./.)
(S (PP-TMP During/IN (NP (NP latent/JJ (NP (NP Epstein-Barr/JJ virus/NN) (PRN -LRB-/-LRB- (NP EBV/NN) -RRB-/-RRB-)) infection/NN) (PP of/IN (NP human/JJ B/NN lymphocytes/NNS)))) ,/, (NP-SBJ-52 (NP six/CD viral/JJ nuclear/JJ antigen/NN) (PRN -LRB-/-LRB- (NP EBNAs/NNS) -RRB-/-RRB-)) (VP are/VBP (VP expressed/VBN (NP *-52/-NONE-) (PP from/IN (NP long/JJ primary/JJ transcripts/NNS)) (PP by/IN means/NNS of/IN (NP-COOD (NP alternative/JJ splicing/NN) and/CC (NP alternative/JJ polyadenylylation/NN sites/NNS))))) ./.)
(S (NP-SBJ These/DT transcripts/NNS) (VP initiate/VBP (PP from/IN (NP (NP one/CD) (PP of/IN (NP (NP (NP two/CD promoters/NNS) ,/, (NP-COOD (NP Cp/NN) or/CC (NP Wp/NN)) ,/,) (SBAR (WHNP-53 that/WDT) (S (NP-SBJ *T*-53/-NONE-) (VP function/VBP (PP in/IN (NP a/DT (ADJP mutually/RB exclusive/JJ) fashion/NN)))))))))) ./.)
(S (NP-SBJ-54 Wp/NN) (VP is/VBZ (ADVP exclusively/RB) (VP utilized/VBN (NP *-54/-NONE-) (PP-TMP during/IN (NP (NP the/DT initial/JJ stages/NNS) (PP of/IN (NP (NP infection/NN) (PP of/IN (NP primary/JJ B/NN lymphocytes/NNS)))))) ,/, (S (NP-SBJ-200 */-NONE-) (VP followed/VBN (NP *-200/-NONE-) (PP by/IN (NP-LGS (NP a/DT switch/NN) (PP to/TO (NP Cp/NN usage/NN)))))))) ./.)
(S (NP-SBJ-55 These/DT studies/NNS) (VP have/VBP (VP been/VBN (VP extended/VBN (S (NP-SBJ *-55/-NONE-) (VP to/TO (VP show/VB (SBAR that/IN (S-COOD (S (LST -LRB-/-LRB- i/LS -RRB-/-RRB-) (NP-SBJ-56 (NP a/DT mutant/JJ EBV/NN strain/NN) (VP lacking/VBG (NP (NP the/DT gene/NN) (VP encoding/VBG (NP EBNA/NN 2/CD))))) (VP fails/VBZ (S (NP-SBJ *-56/-NONE-) (VP to/TO (VP switch/VB (PP (PP from/IN (NP Wp/NN (NP *RNR*-201/-NONE-))) (PP to/TO (NP Cp/NN (NP *RNR*-201/-NONE-))) (NP-201 usage/NN)) (PP in/IN (NP primary/JJ B/NN lymphocytes/NNS)) ,/, (SBAR although/IN (S (NP-SBJ the/DT virus/NN) (VP contains/VBZ (NP a/DT functional/JJ Cp/NN))))))))) ;/: (S (LST -LRB-/-LRB- ii/LS -RRB-/-RRB-) (NP-SBJ (NP a/DT region/NN) (NP (QP from/IN -429/CD to/TO -245/CD) base/NN pairs/NNS) (ADJP upstream/JJ (PP of/IN (NP Cp/NN)))) (VP is/VBZ (ADJP-PRD essential/JJ (PP for/IN (NP (NP Cp/NN activity/NN) (PP in/IN (NP B/NN lymphocytes/NNS)))) ,/, but/CC (PP only/RB in/IN (NP (NP the/DT context/NN) (PP of/IN (NP (ADJP-COOD (ADJP upstream/JJ) and/CC (ADJP downstream/JJ)) sequences/NNS))))))) ;/: (S (LST -LRB-/-LRB- iii/LS -RRB-/-RRB-) (NP-SBJ this/DT region/NN) (VP contains/VBZ (NP an/DT EBNA/NN 2-dependent/JJ enhancer/NN))) ;/: and/CC (S (LST -LRB-/-LRB- iv/LS -RRB-/-RRB-) (NP-SBJ (NP DNase/NN I/CD protection/NN) (VP employing/VBG (NP (NP nuclear/JJ extracts/NNS) (PP from/IN (NP (NP-COOD (NP B/NN) and/CC (NP T/NN)) lymphocytes/NNS))))) (VP revealed/VBD (NP (NP a/DT B-cell-specific/JJ footprint/NN) (PP in/IN (NP (NP the/DT region/NN) (PP of/IN (NP the/DT (ADJP EBNA/NN 2-dependent/JJ) enhancer/NN))))))))))))))) ./.)
(S (NP-SBJ These/DT results/NNS) (VP support/VBP (NP (NP a/DT model/NN) (PP for/IN (NP (NP viral/JJ promoter/NN switching/NN) (PP-TMP during/IN (NP (NP the/DT initial/JJ stages/NNS) (PP of/IN (NP infection/NN))) (SBAR (WHPP-57 in/IN (WHNP which/WDT)) (S (NP-SBJ Wp/NN activity/NN) (VP leads/VBZ (PP to/TO (NP (NP the/DT expression/NN) (PP of/IN (NP EBNA/NN 2/CD)))) (PP *T*-57/-NONE-) ,/, (S-ADV (NP-SBJ-202 */-NONE-) (VP followed/VBN (NP *-202/-NONE-) (PP by/IN (NP-LGS (NP (NP activation/NN) (PP of/IN (NP Cp/NN))) (PP through/IN (NP the/DT (ADJP EBNA/NN 2-dependent/JJ) enhancer/NN)))))))))))))) ./.)
